Journal ArticleOPEN ACCESS

Quantitative mass spectrometry suggests beta‐synuclein as promising blood marker for synaptic degeneration in Alzheimer's disease

  • Oeckl P
  • Halbgebauer S
  • Straub S
  • et al.
Alzheimer's & Dementia (2020) 16(S4)
DOI: 10.1002/alz.040246
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Synaptic degeneration is a major hallmark of Alzheimer's disease (AD)

Cite

CITATION STYLE

APA

Oeckl, P., Halbgebauer, S., Straub, S., von Arnim, C., Diehl‐Schmid, J., Frölich, L., … Otto, M. (2020). Quantitative mass spectrometry suggests beta‐synuclein as promising blood marker for synaptic degeneration in Alzheimer’s disease. Alzheimer’s & Dementia, 16(S4). https://doi.org/10.1002/alz.040246

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free